Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been given a consensus recommendation of “Moderate Buy” by the five brokerages that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $92.60.

PBH has been the subject of several analyst reports. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Oppenheimer increased their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Tuesday. Canaccord Genuity Group increased their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Finally, Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a report on Monday, December 9th.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Prestige Consumer Healthcare by 14.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,315 shares of the company’s stock valued at $649,000 after purchasing an additional 1,030 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at $7,778,000. Kayne Anderson Rudnick Investment Management LLC purchased a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at $84,932,000. Vise Technologies Inc. purchased a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at $319,000. Finally, McIlrath & Eck LLC grew its holdings in shares of Prestige Consumer Healthcare by 19.1% in the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after purchasing an additional 154 shares in the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $84.01 on Wednesday. The firm’s 50 day moving average price is $81.87 and its 200-day moving average price is $78.45. Prestige Consumer Healthcare has a twelve month low of $62.35 and a twelve month high of $90.04. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $4.16 billion, a PE ratio of 19.67, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Equities research analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.